Display Settings:

Format

Send to:

Choose Destination

    Clin Infect Dis. 2001 Oct 1;33(7):983-9. Epub 2001 Sep 5.

    Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population.

    Gray GC, Witucki PJ, Gould MT, Bell SJ, Hiliopoulos KM, McKeehan JA, Fuller JM, Barrozo CP, Hudspeth MK, Smith TC, Ledbetter EK, Wallace MR.

    Department of Defense Center for Deployment Health Research, Naval Health Research Center, San Diego, CA 92186-5122, USA. Gregory-Gray@uiowa.edu

    Military Special Forces trainees undergo intense psychological and physical stressors that often lead to respiratory infection. During 1998-2000, 477 Navy Special Forces trainees were enrolled in a double-blind trial of oral azithromycin (1 g given weekly) plus a placebo injection, compared with benzathine penicillin G (1.2 million U) plus azithromycin placebo tablets. Among the 464 subjects with complete data, 44 developed acute respiratory infection (20 with pneumonia) during the 2 weeks of most intense training; of these subjects, 12 (27.3%) had evidence of Chlamydia pneumoniae infection and 7 (15.9%) had evidence of Mycoplasma pneumoniae infection. Trainees who received azithromycin were less likely than were trainees who received benzathine penicillin G to develop acute respiratory infection (risk ratio, 0.50; 95% confidence interval [CI], 0.28-0.92) and less likely at the end of training to report episodes of breathing difficulty (odds ratio [OR], 0.59; 95% CI, 0.34-1.01) or sore throat (OR, 0.66; 95% CI, 0.41-1.05). Compared with benzathine penicillin G prophylaxis, weekly oral azithromycin was superior in preventing respiratory infection in this population at transient high risk.

    PMID: 11528569 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information